Evaluation of deoxynivalenol detection variability in maize highlights implications for testing accuracy.
Commercial immunoassay-based test kits are widely used for rapid screening of deoxynivalenol (DON) in maize; however, inconsistent results are frequently observed under commercial testing conditions. This study evaluated two distinct contributors to such variability: analytical cross-reactivity of commercial DON immunoassays and between-site variability arising from routine grain elevator testing practices. Under controlled laboratory conditions, all kits accurately measured DON but responded differently to co-occurring DON derivatives. In naturally contaminated maize, immunoassay results reflected the combined presence of DON and co-occurring derivatives, consistent with differences in antibody specificity. An interlaboratory comparison involving multiple grain elevators analyzing identical blinded samples demonstrated substantial between-site variability in reported DON concentrations, with about 16% of results deviating by more than ±20% from the LC–MS/MS reference value. Collectively, these findings show that inconsistent DON test outcomes arise from the combined effects of antibody cross-reactivity and site-specific testing variability, rather than from any unreliability of the analytical methods themselves. This finding highlights the importance of interpreting rapid DON measurements considering these factors.
No takes yet. Share an insight, caveat, or question.
Gedion et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: